System-Specific Biopharmaceuticals

Takeda Pharmaceutical Co. Ltd.

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca PLC

AstraZeneca

Pfizer

Twitter

CORNERSTONE TEC

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

Takeda Pharmaceutical evaluating provision amount for fiscal year ending March 31, 2026

Takeda China Announces Launch of TACare IBD Patient Care 2.0 at Digestive Health Conference

Takeda Pharmaceutical Plans FDA Submission for Psoriasis Drug Zasocitinib

Takeda Pharmaceutical Co - ADR 2026 EPS Forecast Revised Down to 0.32

FactSet: Takeda Pharmaceutical Co - ADR Target Price Raised

Halozyme and Takeda Enter into ENHANZE® Technology Collaboration

Takeda and Protagonist submit NDA for rusfertide

Takeda's TYK2 Inhibitor Zasocitinib Phase III Clinical Trial for Moderate to Severe Plaque Psoriasis Successful

Innovent Biologics and Takeda Enter Global Strategic Collaboration

Innovent Biologics Completes Global Strategic Collaboration and Share Issuance with Takeda

Takeda Publishes New Data on Mezagitamab for IgA Nephropathy

Takeda's Earnings Call: Positive Pipeline Progress, But Generic Competition and Currency Headwinds Lower Profit Guidance

Takeda Dengue Vaccine QDENGA Shows Seven Years of Continuous Protection in Clinical Trials

Takeda Pharmaceutical Sees 40% Drop in Net Profit in First Half of 2023

Takeda revises 2025 fiscal year financial forecast downwards

Takeda Pharmaceutical Expected Earnings and Revenue for Q4 2025

Takeda Launches HyHub Devices to Simplify HYQVIA Infusion Preparation

Sogi Reiterates Strong Buy Rating on Takeda Pharmaceutical with a Price Target of $33.79

Innovent Biologics and Takeda Form Global Collaboration for Cancer Therapy Development

Takeda Decides to Exit Cell Therapy Field

Takeda Pharmaceutical faces an $885 million jury verdict in an antitrust case related to its drug Amitiza. The jury found that a 2014 settlement delayed competition, violating antitrust laws. Takeda plans to appeal, asserting the settlement was lawful and allowed for an authorized generic launch. The damages awarded will triple under U.S. law, with further proceedings pending for additional claims. Takeda's stock rose slightly, but the company has seen a decline over the past month.

benzinga_article

Takeda Pharmaceutical Company

S&P 500

Jury Hits Takeda With $885 Million Antitrust Verdict

Attorneys at Hagens Berman announced a $474.89 million jury verdict against Takeda Pharmaceuticals in a class-action lawsuit over Amitiza. The jury found Takeda liable for antitrust violations related to delaying the launch of a generic version of the drug, resulting in overcharges to consumers. The total damages, including statutory trebling, amount to $1.4 billion. The trial highlighted a pay-for-delay scheme that harmed competition and the healthcare system.

MorningStar

PAR Tech

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Takeda Pharmaceutical Company Limited reported a statutory profit of JP¥122 per share, exceeding analyst expectations, while revenues matched forecasts at JP¥4.5t. Analysts predict a modest revenue increase to JP¥4.61t in 2027, but have downgraded EPS estimates to JP¥137, reflecting a decline in sentiment. The consensus price target remains unchanged at JP¥6,124, indicating stable valuation despite slower growth compared to industry peers. Analysts highlight three warning signs for investors to consider.

Simplywall

Takeda Pharmaceutical Company Limited Just Recorded A 8.6% EPS Beat: Here's What Analysts Are Forecasting Next

Takeda Pharmaceutical Company Limited's 12-month stock price target has been cut to $18.55, indicating a potential upside of 13%. Analysts' average price target has slightly increased from $19.2 to $19.3, with a range of $15.4 to $21.67. The consensus rating remains a 'Buy' from 12 analysts, comprising 7 Buys and 5 Holds. This information is sourced from FactSet and does not constitute investment advice.

TradingView

Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Cut to $18.55, Implies 13% Upside

Takeda Pharmaceutical Co. Ltd.(4502.JP)

Jury Hits Takeda With $885 Million Antitrust Verdict

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Takeda Pharmaceutical Company Limited Just Recorded A 8.6% EPS Beat: Here's What Analysts Are Forecasting Next

Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Cut to $18.55, Implies 13% Upside